Results 21 to 30 of about 2,821 (202)
How Can We Personalize the Delivery of Onabotulinumtoxin-A for Patients With Neurogenic Lower Urinary Tract Dysfunction? [PDF]
Neurourol UrodynABSTRACT Background & Aims Neurogenic lower urinary tract dysfunction (NLUTD) can produce bothersome urinary symptoms, impact quality of life, and in some cases, lead to deterioration of upper urinary tract function. Intradetrusor injection of onabotulinumtoxin‐A (BoNT‐A) is approved for NLUTD in patients who have an inadequate response to or ...
Wang SL, Jaffe WI, Smith AL.
europepmc +2 more sources
Consistencies between carbachol-induced contractions to clinical antimuscarinics in differently aged porcine bladders [PDF]
, 2023 Introduction: The first-line pharmaceutical therapies for managing overactive bladder (OAB) are antimuscarinics (Moro et al., 2011) where they inhibit spontaneous contractions during the filling phase by blocking the actions of acetylcholine.
Moro, Christian; id_orcid +2 more
core +3 more sources
Tzu Chi Medical Journal, 2022 Medical treatment of overactive bladder (OAB) includes antimuscarinic agents, beta-3 adrenoceptor agonist (mirabegron), or combination with both drugs. Recently, a meta-analysis reported the integrated clinical trial data from 10 phase 2–4, double-blind,
Hann-Chorng Kuo
doaj +1 more source
Detrusor responses to antimuscarinics medications is consistent between juvenile and adult urinary bladders in porcine tissue [PDF]
, 2023 Introduction & Objectives: The first-line pharmaceutical therapies for managing overactive bladder (OAB) are antimuscarinics (Moro et al., 2011). Their main mechanism of inhibiting spontaneous contractions in the urinary bladder during the filling ...
Moro, Christian +2 more
core +3 more sources
Perioperative Medicine, 2021 Objectives This meta-analysis aimed to evaluate the efficacy and safety of antimuscarinics for the prevention or treatment of catheter related bladder discomfort (CRBD).
Zhongbao Zhou +5 more
doaj +1 more source
Tzu Chi Medical Journal, 2023 Objectives: To compare the therapeutic efficacy, adverse events (AEs), and patient preference in elderly patients with overactive bladder (OAB) receiving different combinations of mirabegron and solifenacin.
Yuh-Chen Kuo, Hann-Chorng Kuo
doaj +1 more source
Frontiers in Pharmacology, 2023 Objective: We conducted a meta-analysis to assess the efficacy and safety of mirabegron (50 mg/day) and antimuscarinics in treating ureteral stent-related symptoms (SRSs).Methods: All randomized controlled trials (RCTs) were identified by searching ...
Youyi Lu +3 more
doaj +1 more source
Trends and Racial/Ethnic Disparities in Pharmacologic and Surgical Management of Treated Female Patients With Urinary Incontinence. [PDF]
Neurourol UrodynABSTRACT Background The current literature summarizes the trends in the surgical management of stress urinary incontinence (SUI) and not the general trends of management for all UI types in the US. Additionally, recent evidence on racial and ethnic disparities in UI related surgical utilization is limited. Objective To describe the currently prescribed
Almadfaa RO +5 more
europepmc +2 more sources
Pharmacy, 2023 Overactive bladder prevalence increases in older adults often complicating the management of other comorbidities. The theoretical antagonism between the parasympathetic-blocking anticholinergic agent and the parasympathetic stimulatory agents ...
Jonathan H. Watanabe, Tu Hoang
doaj +1 more source
Sex Differences in Prescribing Patterns of Anticholinergics and β3-Adrenoceptor Agonists for Overactive Bladder: A Nationwide Study in Japan, FY2017-FY2024. [PDF]
Low Urin Tract SymptomsABSTRACT Objectives Drug treatment for overactive bladder (OAB) is changing, with an increasing share of β3‐adrenoceptor agonists relative to anticholinergics, but it is not known how far this change has progressed in older people, who are most vulnerable to the risks of anticholinergics.
Koike T +9 more
europepmc +2 more sources